Brainsway Ltd ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
44.2%projected annual EPS growth
Analyst Coverage
3analysts covering
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 18 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Deep TMS Systems Shipped Quarterly117.0
Total Installed Base (Systems) Quarterly1.8K
Remaining Performance Obligations (RPO) Quarterly75M
Watch Items
- FDA clearance for Deep TMS in PTSD with MDDTrigger: Regulatory approval decision expected before year-end 2026Action: Monitor FDA announcements and company press releases for clearance status and subsequent Q4 marketing push.
- Strategic minority-stake clinical platform investmentsTrigger: Execution of milestone-based follow-on investments in Hopemark Health, BrainStim Health, and NeuroliefAction: Track clinical expansion, system placements, and cash deployment efficiency across North American mental health providers.
Research as of 20 Jun 2026